Hemostemix is a public biotechnology-based company listed on TSX-V, with HEM as the ticker symbol. Hemostemix is right now zeroing in on propelling its leading candidate, ACP-01, an autologous cell treatment, which as of its 2nd phase clinical trial in the United States and Canada.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.